Skip to main content
. 2021 Jun 30;10(13):2939. doi: 10.3390/jcm10132939

Table 4.

Baseline characteristics, DSS relevant parameters and outcome variables depending on therapy delays in the CytoSorb group. Presented are mean values ± standard deviations, frequency and percent (%) and levels of significance.

Therapy Delay
≤12 h (n = 80)
Therapy Delay
>12–24 h (n = 65)
Therapy Delay
>24 h (n = 53)
p-Value
(<12 vs. 12–24 h)
p-Value
(<12 vs. >24 h)
p-Value
(12–24 vs. >24 h)
Age (years) 62.0 (±13.72) 61.2 (±16.06) 64.1 (±15.28) 0.670 0.410 0.310
APACHE II (points) 32.7 (±9.38) 36.2 (±9.31) 32.7 (±11.53) 0.028 0.994 0.078
SAPS II (points) 64.2 (±19.26) 56.1 (±14.93) 56.7 (±16.96) 0.007 * 0.021 0.850
Ventilator days 12.9 (±18.50) 13.2 (±19.11) 13.0 (±16.93) 0.930 0.996 0.937
ICU stay (days) 20.2 (±25.80) 19.9 (±23.95) 18.0 (±19.49) 0.930 0.578 0.643
Hospital stay (days) 28.1 (±39.99) 32.1 (±42.71) 25.0 (±29.98) 0.560 0.609 0.293
ICU mortality (%) 40 (50.0%) 39 (60.0%) 39 (73.5%) 0.231 0.006 * 0.123
Hospital mortality (%) 45 (56.2%) 40 (61.5%) 42 (79.2%) 0.430 0.006 * 0.038
CytoSorb therapy delay (hours) 6.8 (±4.50) 20.4 (±3.99) 54.6 (±25.92) <0.001 * <0.001 * <0.001 *
Number of CytoSorb adsorbers used (n) 3.03 (±1.66) 2.69 (±1.62) 2.24 (±0.97) 0.211 0.002 * 0.082
Lactate T0 (mmol/L) 4.73 (±3.48) 5.11 (±3.90) 4.38 (±3.55) 0.540 0.574 0.292
Lactate T6 (mmol/L) 5.09 (±3.63) 5.05 (±3.67) 3.80 (±3.00) 0.940 0.034 0.046
Norepinephrine T0 (µg/kg/min) 0.50 (±0.65) 0.45 (±0.26) 0.42 (±0.37) 0.506 0.323 0.613
Norepinephrine T6 (µg/kg/min) 0.64 (±0.46) 0.54 (±0.35) 0.50 (±0.40) 0.153 0.083 0.647
Second catecholamine T0 (%) 64 (80.0%) 25 (38.0%) 22 (41.5%) <0.001 * <0.001 * 0.740
Hydrocortisone T0 (%) 63 (78.7%) 44 (67.6%) 29 (56.6%) 0.134 0.008 * 0.235
Volume bolus used (mL/kg) 75.0 (±25.8) 81.6 (±28.8) 78.0 (±27.6) 0.122 0.510 0.444
Dynamic Scoring System (points) 8.48 (±1.53) 7.60 (±1.58) 7.01 (±2.19) 0.001 * <0.001 * 0.093

* = Statistically significant using Bonferroni-adjusted alpha critical value = 0.017.